Navigation Links
Remove Diabetes Drug Avandia From Market: FDA Reports
Date:2/20/2010

Controversial medicine raises users' heart risk, leaked documents suggest

SATURDAY, Feb. 20 (HealthDay News) -- The blockbuster type 2 diabetes drug Avandia raises users' odds for heart attack and heart failure and should be removed from the market, according to confidential government reports.

The New York Times on Saturday reported on documents from the U.S. Food and Drug Administration that find that if people now taking (rosiglitazone) Avandia switched to a similar medication, Actos, about 500 heart attacks and 300 cases of heart failure would be eliminated each month. And in a report from the Institute for Safe Medication Practice, Avandia was linked to 304 deaths in the third quarter of 2009 alone, the highest for any prescribed drug in that time period, the Times reported.

In one of the FDA documents, dated October 2008, Drs. David Graham and Kate Gelperin -- drug safety officials at the agency -- agreed that "rosiglitazone should be removed from the market."

The reports, obtained early by the Times, are yet another chapter in Avandia's checkered history. The drug was once taken by millions worldwide, but that changed after a study released in early May of 2007 by the Cleveland Clinic suggested that Avandia carried cardiovascular risks. That study, which included more than 28,000 people, found that Avandia increased a user's odds of heart attack by 43 percent compared to those not taking the medicine.

At the time, Dr. Bruce M. Psaty of the University of Washington -- who also co-wrote an accompanying editorial in the New England Journal of Medicine -- urged the FDA to restrict access to Avandia and cited both the agency and the drug's maker, GlaxoSmithKline, for poor oversight.

"The primary problem here is that studies that were needed early on about the health benefits of this drug were never done," Psaty told HealthDay. "As a result of the failure of
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
2. Surgeons Remove Gallbladder Through Vagina
3. CVS/pharmacy to Remove OTC Infant Cough & Cold Products from Its Stores as Part of CHPAs Voluntary Withdrawal
4. Prominent Farmington Plastic Surgeon Uses Two New Non-Surgical Procedures to Tighten Skin and Remove Fat
5. Stop & Shop Removes Childrens Cough and Cold Medicine from Store Shelves
6. Giant Food Removes Childrens Cough and Cold Medicine From Store Shelves
7. Schwarzenegger Signs Bill to Remove Written Informed Consent for HIV Testing; "Most Important Change in Public HIV/AIDS Policy in Years," Says AHF
8. Health Groups Call on Cosmetic Giant LOreal to Remove Lead From Lipstick
9. Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure
10. Nations Largest Pet Insurer Reveals Top 10 Items Surgically Removed From Pets
11. Safety Concerns Prompt Prime to Remove Avandia(R) from Formulary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 Healthcare staffing agency ... Nurses of Tomorrow Scholarship Competition winners:, ... NV ,     Racheal D., Freshman, Cerritos College ... Houston Community College in Houston, TX ... Medical Solutions hosts the Nurses of Tomorrow Scholarship ...
(Date:7/29/2014)... 29, 2014 Catalent Pharma Solutions, ... advanced delivery technologies for pharmaceutical, biologic, and consumer ... R&D Director and US Platform Leader of Pharmaceutical ... Drugs with Lipid-Based Formulations using Soft Capsule Delivery ... the Japan Society of Drug Delivery Systems (30-31 ...
(Date:7/29/2014)... The Affordable Care Act has created a dramatic ... show that over 400 hospitals probably won’t survive this ... that great hospitals use to survive the threat increases ... secret? Debriefing - the simple process of systematically offering ... operational event. Debriefing is a standard procedure in military ...
(Date:7/29/2014)... Dennis Thompson HealthDay Reporter , MONDAY, ... three years longer than people who don,t run, according to new ... that it appears that you can reap this benefit even if ... 15-year study suggests. "People may not need to run ... an assistant professor of kinesiology at Iowa State University. "I hope ...
(Date:7/29/2014)... Kelly and Zhi Sheng , assistant professors ... recently received a grant from the Commonwealth Health ... effort that may lead to new treatment approaches. , ... , The grant will fund a two-year project to ... the BRCA1 gene. This type of cancer often has ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Announces Nurses of Tomorrow Scholarship Winners 2Health News:Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Running Could Add 3 Years to Your Lifespan 2Health News:Running Could Add 3 Years to Your Lifespan 3Health News:Scientists to study hereditary breast cancer to find BRCA1 treatment 2
... Better ... Treatment Options, WASHINGTON, Nov. 2 Today, the ... for interventional cardiology, announced the,launch of Seconds Count, a ... an authoritative resource about cardiovascular disease and,treatment. The program ...
... AMED or the "Company"), one of America,s leading home ... and,Chief Operating Officer, and Dale E. Redman, Chief Financial ... Annual Healthcare Conference in,New York on Tuesday, November 6, ... Eastern time. The audio,presentation will be webcast live and ...
... inhibitor demonstrates >99% mean decrease in HCV RNA ... with no serious adverse events-, ... the results of a 14-day Phase 1 multiple ascending,dose monotherapy study ... study, being presented as a "late-breaker" abstract at,the 58th Annual Meeting ...
... IDM Pharma, Inc.,(Nasdaq: IDMI ) today announced ... mifamurtide (L-MTP-PE) in patients,with lung metastases as a result ... bone tumor that typically affects children and young,adults. The ... is,safe, well-tolerated and exhibited signs of disease control. ...
... Medical,s blood loss detection,device for monitoring venous needle ... available for sale in the United States. The ... the world,s,first such device. Having met Europe,s rigorous ... granted CE approval. With the FDA,s approval,Redsense is ...
... Statement by James Wagoner on the $28 ... Nov. 1 The following is a,statement ... increase in abstinence-only,program funding:, Today, we ... committee report includes the full $28 million,increase ...
Cached Medicine News:Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 2Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 3Health News:Amedisys to Present at 2007 CIBC Healthcare Conference in New York 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 3Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 4Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 5Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 2Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 3Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 4Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 5Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 6Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 7Health News:Redsense Medical Receives FDA Approval for Blood Loss Detection Device 2Health News:Redsense Medical Receives FDA Approval for Blood Loss Detection Device 3Health News:Democrats Cave on Sex Education - Again 2
(Date:7/29/2014)... 2014 China Biologic Products, Inc. (NASDAQ: CBPO, ... plasma-based biopharmaceutical company in China , ... quarter 2014 financial results on Tuesday, August 5, 2014 ... management will hold a conference call at 8:00 a.m. ... p.m., Beijing Time on August 6, 2014, to discuss ...
(Date:7/29/2014)... 29, 2014 , Next ... development program has commenced , TPM®/Oxycodone Phase ... during Q4 2014 , TPM®/Oxymorphone Phase 2 ... 1H 2015 Australian drug delivery company, Phosphagenics ... transdermal patch programs after its recent announcement of a $19.2 million ...
(Date:7/29/2014)...   , First patient ... efficacy and safety of MSB0010718C in patients with metastatic Merkel ... aggressive skin cancer lacking effective treatments   MSB0010718C is ... clinical trial for the treatment of solid tumors that aims ... a subsidiary of Merck KGaA, Darmstadt, Germany ...
Breaking Medicine Technology:China Biologic to Report Second Quarter 2014 Financial Results 2China Biologic to Report Second Quarter 2014 Financial Results 3Phosphagenics Provides Update on Opioid Patch Program 2Phosphagenics Provides Update on Opioid Patch Program 3Phosphagenics Provides Update on Opioid Patch Program 4Phosphagenics Provides Update on Opioid Patch Program 5Phosphagenics Provides Update on Opioid Patch Program 6EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5
... /Xinhua-PRNewswire/ -- NeuroAid(TM) is the first,natural compound to ... on stroke,recovery starting in the acute stage. ... trial to evaluate the efficacy of NeuroAid(TM) in ... with treatment starting within 48 hours of a ...
... 26 Rcadia Medical Imaging, Ltd.,developer of novel ... Food and Drug Administration (FDA) clearance to market,its ... triaging patients for,coronary artery disease (CAD). The new ... human intervention and automatic detection of,pathologies in the ...
Cached Medicine Technology:International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery 2International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery 3International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery 4Rcadia's COR Analyzer Family of Products Receives Second FDA Clearance 2
A custom blend for Applied Biosystems by FMC. Designed specifically for the electrophoresis of PCR products....
... for screening donors on the PK7200 Automated ... CMV antigen attached to a gelatin particle ... and specificity of the CMV assay as ... respectively. The use of a gelatin particle ...
The Ortho AutoVue System is an automated immunohematology testing system used for blood typing, antibody screening and compatibility testing using Ortho BioVue System cassettes....
... designed for medium to ... centers and reference laboratories ... antibody screening. It will ... functions including blood group ...
Medicine Products: